The company's products in development include UBX 1325, which targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases (in Phase 1 clinical trials for diabetic macular edema as of October 2020). In July 2022, the company reported positive results from its Phase 1 study.[8] They also include UBX 1967, a preclinical product targeting ophthalmologic diseases.[9][10][11] Both products are senolytic medicines.
On May 3, 2018, the company went public on the Nasdaq exchange, raising $85 million at a market capitalization of $700 million.[12][10] Unity Biotechnology shares dropped 60% on August 17, 2020, after the company reported disappointing results from a clinical trial involving its lead drug candidate, UBX0101, in patients with moderate-to-severe painful osteoarthritis.[13]
^Brueck, Hilary (3 February 2016). "Mayo Clinic Taps Silicon Valley to Help People Age Gracefully". Fortune. Retrieved 19 February 2018.
^Detrixhe, John (21 February 2018). "Crypto millionaires are funding research to reverse the aging process". Quartz (publication). Retrieved 19 February 2018.
^Herkewitz, William (19 February 2018). "Scientists Can Now Radically Expand the Lifespan of Mice—and Humans May Be Next". Popular Mechanics. Retrieved 19 February 2018.
^Ramsey, Lydia (10 November 2016). "A biotech startup that aims to rid our bodies of cells related to aging just got a big investment". Business Insider. Retrieved 19 February 2018.
^Scudellari, Megan (25 February 2017). "To Stay Young, Kill Zombie Cells". Scientific American. Retrieved 19 February 2018.
^Greenfieldboyce, Nell (3 February 2016). "Boosting Life Span By Clearing Out Cellular Clutter". Retrieved 19 February 2018.
^Baker, Darren (11 February 2016). "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan". Nature. 530 (7589): 184–189. doi:10.1038/nature16932. PMC4845101. PMID 26840489.
^Bankhead, Charles (2022-07-14). "'Senolytic' Therapy Shows Promise in Neovascular Eye Disease". www.medpagetoday.com. Retrieved 2022-07-15.
unity, biotechnology, publicly, traded, american, biotechnology, company, that, develops, drugs, that, target, senescent, cells, typepublictraded, asnasdaq, ubxrussell, 2000, componentindustrybiotechnology, pharmaceuticalpredecessorforge, founded2011, years, 2. Unity Biotechnology is a publicly traded American biotechnology company that develops drugs that target senescent cells 1 2 3 4 5 6 7 Unity BiotechnologyTypePublicTraded asNasdaq UBXRussell 2000 componentIndustryBiotechnology PharmaceuticalPredecessorForge Inc Founded2011 12 years ago 2011 in California United States of AmericaFoundersJudith CampisiJan van DeursenNathaniel DavidDaohong ZhouHeadquartersSouth San Francisco California United States of AmericaNumber of employees70 2018 Websiteunitybiotechnology wbr comThe company s products in development include UBX 1325 which targets Bcl xL a mechanism to eliminate senescent cells in age related eye diseases in Phase 1 clinical trials for diabetic macular edema as of October 2020 In July 2022 the company reported positive results from its Phase 1 study 8 They also include UBX 1967 a preclinical product targeting ophthalmologic diseases 9 10 11 Both products are senolytic medicines On May 3 2018 the company went public on the Nasdaq exchange raising 85 million at a market capitalization of 700 million 12 10 Unity Biotechnology shares dropped 60 on August 17 2020 after the company reported disappointing results from a clinical trial involving its lead drug candidate UBX0101 in patients with moderate to severe painful osteoarthritis 13 See also EditSenolytics CalicoReferences Edit Brueck Hilary 3 February 2016 Mayo Clinic Taps Silicon Valley to Help People Age Gracefully Fortune Retrieved 19 February 2018 Detrixhe John 21 February 2018 Crypto millionaires are funding research to reverse the aging process Quartz publication Retrieved 19 February 2018 Herkewitz William 19 February 2018 Scientists Can Now Radically Expand the Lifespan of Mice and Humans May Be Next Popular Mechanics Retrieved 19 February 2018 Ramsey Lydia 10 November 2016 A biotech startup that aims to rid our bodies of cells related to aging just got a big investment Business Insider Retrieved 19 February 2018 Scudellari Megan 25 February 2017 To Stay Young Kill Zombie Cells Scientific American Retrieved 19 February 2018 Greenfieldboyce Nell 3 February 2016 Boosting Life Span By Clearing Out Cellular Clutter Retrieved 19 February 2018 Baker Darren 11 February 2016 Naturally occurring p16Ink4a positive cells shorten healthy lifespan Nature 530 7589 184 189 doi 10 1038 nature16932 PMC 4845101 PMID 26840489 Bankhead Charles 2022 07 14 Senolytic Therapy Shows Promise in Neovascular Eye Disease www medpagetoday com Retrieved 2022 07 15 S 1 www sec gov Retrieved 2018 10 12 a b Longevity Company Unity Biotechnology Stocks Soared After CEO Talks to CNBC BioSpace BioSpace Retrieved 2018 10 12 Unity Biotechnology to focus on senolytic programs in ophthalmology neurology www healio com Retrieved 2020 12 08 CNBC 2018 05 02 UNITY Biotechnology Inc Announces Pricing of Initial Public Offering of Common Stock CNBC Retrieved 2018 10 12 Buzzy anti aging biotech Unity drops leading program after flop shares in freefall 2020 08 17 External links EditOfficial website This United States corporation or company article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Unity Biotechnology amp oldid 1110648030, wikipedia, wiki, book, books, library,
